Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVW3 | ISIN: US00091E1091 | Ticker-Symbol:
NASDAQ
26.06.25 | 21:59
2,710 US-Dollar
0,00 % 0,000
1-Jahres-Chart
ABSCI CORPORATION Chart 1 Jahr
5-Tage-Chart
ABSCI CORPORATION 5-Tage-Chart

Aktuelle News zur ABSCI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.06.Absci Corp - 8-K, Current Report3
14.05.Assessing Absci: Insights From 6 Financial Analysts3
14.05.Absci signals expanded clinical pipeline with ABS-101 in Phase I and ABS-201 targeting early 2026 trial3
ABSCI Aktie jetzt für 0€ handeln
13.05.Absci GAAP EPS of -$0.21 beats by $0.02, revenue of $1.18M beats by $0.11M3
13.05.Absci Corp - 10-Q, Quarterly Report3
13.05.Absci Corp - 8-K, Current Report2
13.05.Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease165Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing...
► Artikel lesen
28.04.Absci Corp - 8-K, Current Report4
14.04.Absci Corporation: Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 20251
09.04.Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)3
24.03.KeyBanc maintains Absci stock Overweight rating, $5 target4
19.03.A Glimpse Into The Expert Outlook On Absci Through 7 Analysts4
19.03.H.C. Wainwright maintains $7 target on Absci stock with Buy rating3
18.03.Absci Corp - S-8, Securities to be offered to employees in employee benefit plans1
18.03.Absci Corp - 10-K, Annual Report2
18.03.Absci Corp - 8-K, Current Report1
18.03.Absci GAAP EPS of -$0.25 misses by $0.01, revenue of $0.7M misses by $1.07M2
18.03.Absci Corporation: Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results458Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci...
► Artikel lesen
04.03.Absci Corporation: Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 202516
04.03.Absci Corporation: Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)287VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company...
► Artikel lesen
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1